PYC Therapeutics Limited (ASX:PYC)

Market Cap	717.41M
Revenue (ttm)	24.99M
Net Income (ttm)	-48.20M
Shares Out	583.26M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,282
Average Volume	534,016
Open	1.250
Previous Close	1.230
Day's Range	1.230 - 1.280
52-Week Range	0.950 - 2.000
Beta	0.63
RSI	54.88
Earnings Date	May 28, 2025

About PYC Therapeutics

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease. PYC Therapeuti...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 5
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PYC

Financial Performance

In 2024, PYC Therapeutics's revenue was 22.06 million, an increase of 39.56% compared to the previous year's 15.81 million. Losses were -37.73 million, 65.5% more than in 2023.